Anzeige
❌
Mehr »
Samstag, 10.10.2026 - Börsentäglich über 12.000 News
Elevate Sercive Group: Neue Expertise für den nächsten Wachstumsschritt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
Actusnews Wire
510 Leser
Artikel bewerten:
(2)

DMS IMAGING: Record quarterly revenue: EUR 10.1 million in the 1st quarter of 2023, organic growth +16% - Confirmation of 2023 targets and perspectives

Record quarterly revenue: €10.1 million in the 1st quarter of 2023, organic growth +16%

  • Radiology: 6% growth in 1st quarter / +22% in the United States / First deliveries of record order from Fujifilm Healthcare Italy will begin 2nd quarter

  • Bone densitometry: strong quarterly growth: +69%

Confirmation of 2023 targets and perspectives

  • €40 million in revenue, i.e., double-digit organic growth

  • Expected increase in EBITDA margin

Liège (Belgique) - DMS Imaging (Euronext Brussels and Paris - BE0974289XXX - DMSIM), imaging division of DMS Group and French specialist in the development, design and manufacture of imaging systems, announces its consolidated revenue for the 1st quarter of 2023 (period from January 1 to March 31, 2023).

Unaudited consolidated data in M€
IFRS standards
1st quarter 20231st quarter 2022Change
Revenue10.18.7+16%
Radiology activity7.77.3+6%
Bone densitometry activity2.41.4+69%

DMS Imaging generated consolidated revenue of €10.1 million in the 1st quarter 2023 representing +16% of organic growth and marking the largest quarterly revenue ever earned in a 1st quarter.

Review by activity

In Radiology, revenue amounted to €7.7 million, a quarterly growth of +6%. 1st quarter activity did not include any deliveries of the 96 FDX Visionary-RF Premium remote-controlled radiology tables won in a tender by Fujifilm Healthcare Italy[1]. The first deliveries for this order will begin in the 2nd quarter of 2023 and will ramp up throughout the year.

The Radiology business continued its strong development in the United States at the start of the exercise, with +22% growth in the region, driven by distribution agreements with Fujifilm Healthcare and Carestream Health. DMS Imaging manufactures white-label remote-controlled radiology tables offered by:

  • Fujifilm Healthcare in Europe, Africa, Middle East, and North America.
  • Canon Medical Systems Europe in the Europe area.
  • Carestream Health in North and South America.

DMS Imaging also markets its solutions under its own brand, Apelem, to a network of 140 distributors around the world.

In Bone densitometry, the Group registered a strong 1st quarter 2023, recording +69% growth. This performance reflects the success of our distribution agreement with Fujifilm Healthcare as well as an acceleration in sales in Europe and Asia, where sales activities had begun to resume at the end of 2022.

Confirmation of 2023 revenue target: €40 million

At the end of an historic 1st quarter, DMS Imaging remains confident in its objective of €40 million consolidated annual revenue. The Radiology activity will begin deliveries of the 96 tables to Fujifilm Healthcare Italy over the next few quarters, and sustained activity in both radiology and bone densitometry will allow the Group to reach double-digit organic growth compared to 2022.

The Group also confirms the improvement in its profitability in 2023 , with an expected improvement in its EBITDA margin[2].

As set forth in the Imaging 2027 plan of DMS Group, DMS Imaging has fixed the objectives of registering €60 million revenue and an EBITDA margin of 14% in 2027.

Financial calendar 2023

DateEvent
April 28th 2023Publication of 2022 annual results
July 20th 2023Publication of 2023 1st semester revenue
September 29th 2023Publication of 2023 half-year results
October 19th 2023Publication of 2023 3rd quarter revenue
January 18th 2024Publication of 2023 annual revenue
April 30th 2024Publication of 2023 annual results

The publications will be made when the Euronext Paris market is closed. These dates are given as an indication, they can be changed if necessary.

About DMS Imaging
Specialized in high technology for medical diagnosis, DMS Imaging is now the French leader in development, design and manufacture of RF imaging systems dedicated to radiology, bone densitometry, 3D modeling and posturology.
DMS Imaging is quoted on the Euronext market in Brussels and Paris (ISIN: BE0974289XXX - memo: DMSIM).
More information on www.dms-imaging.com.

Contacts

DMS Imaging
Samuel SANCERNIChief Executive Officer+33 (0)4 67 50 49 00
ACTUS FINANCE
Mathieu OMNES
Fatou-Kiné N'DIAYE
Investor relations
Press relations
+33 (0)1 53 67 36 92
+33 (0)1 53 67 36 34


[1] Read press release of January 12, 2023

[2] EBITDA corresponds to the recurring operating income before interest, taxes, depreciations, and amortization.

------------------------
This publication embed "Actusnews SECURITY MASTER".
- SECURITY MASTER Key: xZycacqYY2mcy3GaZMZtl5Rnm5uUl2WabmKXmGeZl5rHnW+SlWmVaZSeZnBqmWtm
- Check this key: https://www.security-master-key.com.
------------------------
Full and original release in PDF format:
https://www.actusnews.com/documents_communiques/ACTUS-0-79460-dms-imaging_pr_revenue-q1-2023_20042023_en.pdf

© Copyright Actusnews Wire
Receive by email the next press releases of the company by registering on www.actusnews.com, it's free
© 2023 Actusnews Wire
KI-Euphorie kippt - Bei diesen 5 Aktien droht der Crash!
Drei Jahre lang kannten KI-Aktien fast nur eine Richtung: nach oben. Billionenschwere Investitionspläne von Alphabet, Amazon, Meta und Microsoft haben Halbleiter- und Infrastrukturwerte auf immer neue Höhen getrieben. Doch jetzt bekommt die Erfolgsstory gefährliche Risse.

Steigende Anleiherenditen verteuern die Finanzierung, während die gewaltigen KI-Ausgaben zunehmend nicht mehr aus den laufenden Cashflows bezahlt werden können. Gleichzeitig zeigen günstigere chinesische Modelle, dass leistungsfähige KI womöglich mit deutlich weniger Rechenleistung auskommt. Damit wächst die Gefahr, dass heute für Milliarden errichtete Kapazitäten morgen nicht die erhofften Renditen liefern.

Für Anleger könnte das zum Problem werden. Denn treffen steigende Finanzierungskosten auf Überkapazitäten und enttäuschende Cashflows, geraten gerade hoch bewertete KI-Profiteure schnell unter Druck. Aus den größten Gewinnern der vergangenen Jahre könnten so die größten Verlierer der nächsten Korrektur werden.

In unserem aktuellen Spezialreport zeigen wir 5 Aktien, bei denen das Chance-Risiko-Verhältnis jetzt besonders gefährlich erscheint – und bei denen Anleger genauer hinschauen sollten.

Jetzt den kostenlosen Report sichern – bevor die KI-Euphorie ihren nächsten Realitätstest erlebt!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.